Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Uralsib reported for 6 months of 2024 by RAS

7/22/24 USBN

MTS-Bank reported for 6 months of 2024 by RAS

7/22/24 MBNK

State-owned shareholding of TGC-2 is transferred to GEKH management

7/22/24 TGKB

T-Bank reported for for 6 months of 2024 by RAS

7/22/24 T

Sovcombank reported for 6 months of 2024 by RAS

7/22/24 SVCB

Positive Technologies reported for 6 months of 2024 by RAS

7/22/24 POSI

Positive Technologies reported for 6 months of 2024 by IFRS

7/22/24 POSI

Positive Technologies shipments in the 1st half of the year grew by 8%

7/22/24 POSI

RussNeft reported for 6 months of 2024 by RAS

7/22/24 RNFT

VTB reports for 6 months of 2024 by RAS

7/22/24 VTBR